No Data
Sunshine Nuohe (688621.SH): The clinical trial application for BTS0327 has been accepted.
On February 11, Gelonghui reported that Sunshine Novartis (688621.SH) announced that its subsidiary Jiangsu Novartis Biotech Co., Ltd. has received the "Acceptance Notification" approved by the National Medical Products Administration, and the clinical trial application for Novartis Biotech's research project BTS0327 has been accepted. BTS0327 is intended to prevent acute and delayed nausea and vomiting caused by chemotherapy.
Sunshine Novo (688621.SH): has repurchased a total of 1.60% of the company's shares.
On January 21, Gelonghui reported that Sunlight Novo (688621.SH) announced that as of January 21, 2025, the company has repurchased a total of 1.787962 million shares through centralized bidding transactions, accounting for 1.60% of the company's current total share capital of 112,000,000 shares. The highest purchase price was 37.82 yuan/share, the lowest price was 34.46 yuan/share, and the total amount paid was 64.481263 million yuan (excluding stamp duty, trading commissions, and other transaction costs).
In 2025, the first on the Star! Sunlight Nuohe disclosed the Share Buyback Shareholding loan contract with an interest rate of 1-year LPR minus 115 basis points.
① The loan contract interest rate of Shandong Longertek Technology is a fixed rate, which is the LPR rate minus 85 basis points; ② As of now, three companies listed on the Star have signed contracts with Banks. In addition to Sunshine Nuohua, there are also Suzhou Jinhong Gas Co.,Ltd. and Laier Technology, but neither has disclosed the specific loan interest rate details.
Sunshine Novo (688621.SH) signed a Share Buyback Shareholding Loan Agreement with Banks.
On January 8, Gelonghui announced that Sunlight Nuohuo (688621.SH) has signed a "Share Buyback Shareholding Loan Agreement" with the Beijing Changping District Branch of China Postal Savings Bank Co., Ltd., based on confidence in the company's future development and high recognition of its long-term value. To further improve the company's capital efficiency and fully utilize the national support policy for the share buyback of listed companies, the loan amount is 90 million yuan, specifically for the share buyback of Sunlight Nuohuo (stock code 688621), and the borrower shall not change the intended use of the loan as stipulated in this agreement.
Sunshine Nuohe (688621.SH): Currently, stable synthesis of drugs such as Semaglutide and Tirzepatide has been achieved using solid-phase synthesis technology.
On December 23, Glonghui reported that Sunlight Novo Nordisk (688621.SH) stated on the investor interaction platform that its wholly-owned subsidiary Chengdu Novo Nordisk Shengtai Biotechnology Co., Ltd. has established a distinctive innovative research and development platform for peptide and peptide-like drugs, creating a unique model for innovative drug development. The company is currently able to stably synthesize drugs such as Semaglutide and Teriparatide using solid-phase synthesis technology, and in-depth research can be conducted based on market and business layout. Currently, the company is conducting a total of 6 clinical trial services for GLP-1 class innovative drugs, covering indications for weight loss and blood sugar control, which are in the clinical phase.
Sunshine Novo (688621.SH): As of now, the trend of new customers and Orders is good.
On December 23, Gelo Exchange reported that Sunshine Novo (688621.SH) disclosed its investor relations activity record showing that the integrated R&D service model of "preclinical + clinical" exhibits significant competitive advantages. This model can fully meet the diverse service needs of clients, thereby enhancing the success rate and efficiency of drug development. This advantage helps strengthen the company's ability to secure Orders. In the face of increasing competition within the Industry, the company has adopted a more proactive market expansion strategy by regularly communicating with clients for project planning to ensure precise alignment of R&D services. As of now, new clients and Orders have been developed.
